Skip to main content
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;29(5):204–210. doi: 10.1002/clc.4960290507

An early revascularization strategy is associated with a survival benefit for diabetic patients in cardiogenic shock after acute myocardial infarction

Michael E Farkouh 1,, Krishnan Ramanathan 2, Eve D Aymong 3, John G Webb 3, Shannon M Harkness 4, Lynn A Sleeper 4, Judith S Hochman 1
PMCID: PMC6654055  PMID: 16739392

Abstract

Background: The role of diabetes mellitus (DM) in cardiogenic shock (CS) complicating an acute myocardial infarction (AMI) is not well understood. Previous studies have reported an in‐hospital mortality rate for patients with DM and CS of about 60%.

Objectives: This study compares the 1‐year mortality rates of patients with DM and those without (NDM) and evaluates early revascularization (ERV) compared with initial medical stabilization (IMS) in patients with DM and CS.

Methods: Baseline characteristics, clinical and hemodynamic measures, and management were compared for 90 patients (31%) with DM and 198 with NDM (69%) who were randomized to ERV or IMS in the SHOCK Trial.

Results: When compared with NDM, patients with DM were of similar age but had higher rates of prior MI (44.4 vs. 27.8%, p = 0.007) and hypertension (56.2 vs. 42.5%, p = 0.04). The DM group had a lower rate of fibrinolytic therapy (44.4 vs. 60.1%, p = 0.02). In patients randomized to ERV, patients with DM had a higher rate of coronary artery bypass grafting (CABG) (50.0 vs. 30.9%, p = 0.03) despite similar rates of triple‐vessel disease. The 1‐year mortality rates in both groups were equivalent (58.9%). One‐year mortality was not associated with diabetes (hazard ratio [HR] 1.02, 95% CI, 0.73‐1.42, p = 0.91). The benefit of an ERV strategy was similar (HR [DM] 0.62; HR [NDM] 0.75, p = 0.58). Even after adjusting for the imbalance in CABG rates, 1‐year mortality was not associated with DM.

Conclusion: Diabetes mellitus is not a predictor of 1‐year mortality in CS after AMI. The benefit from an ERV strategy is similar for DM and NDM. The management strategies and influence of DM on mortality in CS deserve further evaluation.

Keywords: cardiogenic shock, acute myocardial infarction, outcomes, diabetes, mortality

Full Text

The Full Text of this article is available as a PDF (41.3 KB).

References

  • 1. Zeller M, Cottin Y, Brindisi MC, Dentan G, Laurent Y, Janin‐Manificat L, L'Huillier I, Beer JC, Touzery C, Makki H, Verges B, Wolf JE, for the RICO Survey Working Group : Impaired fasting glucose and cardiogenic shock in patients with acute myocardial infarction. Eur Heart J 2004; 25: 308–312 [DOI] [PubMed] [Google Scholar]
  • 2. Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS, and the NRMI Investigators : Trends in revascularization and mortality in patients with cardiogenic shock complicating acute myocardial infarction. J Am Med Assoc 2005; 294(4): 448–454 [DOI] [PubMed] [Google Scholar]
  • 3. Berger PB, Tuttle RH, Holmes DR Jr, Topol EJ, Aylward PE, Horgan JH, Califf RM: One‐year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: Results from the GUSTO‐I trial. Circulation 1999; 99: 873–878 [DOI] [PubMed] [Google Scholar]
  • 4. Menon V, Webb JG, Hillis LD, Sleeper LA, Abboud R, Dzavik V, Slater JN, Forman R, Monrad ES, Talley JD, Hochman JS: Diabetes mellitus in cardiogenic shock complicating acute myocardial infarction: Areport from the SHOCK Trial Registry. J Am Coll Cardiol 2000; 36 (3 suppl A, ): 1097–1103 [DOI] [PubMed] [Google Scholar]
  • 5. Casella G, Savonitto S, Chiarella F, Gonzini L, Di Chiara A, Bolognese L, De Servi S, Greco C, Zonzin P, Coccolini S, Maggioni AP, Boccanelli A, and the BLITZ‐1 Study Investigators : Clinical characteristics and outcome of diabetic patients with acute myocardial infarction. Data from the BLITZ‐1 study. Ital Heart J 2005; 6(5): 374–383 [PubMed] [Google Scholar]
  • 6. Hochman JS, Sleeper LA, Godfrey E, McKinlay SM, Sanborn T, LeJemtel T, for the SHOCK Trial Study Group : Should we emergently revascularize Occluded Coronaries for cardiogenic shocK: An international randomized trial of emergency PTCA/CABG‐trial design. Am Heart J 1999; 137: 313–321 [DOI] [PubMed] [Google Scholar]
  • 7. Picard MH, Davidoff R, Sleeper LA, Mendes LA, Thompson CR, Dzavik V, Steingart R, Gin K, White HD, Hochman JS: Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation 2003; 107(2): 279–284 [DOI] [PubMed] [Google Scholar]
  • 8. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater LN, Col J, McKinlay SM, LeJemtel TH, for the SHOCK Investigators : Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341: 625–634 [DOI] [PubMed] [Google Scholar]
  • 9. Tedesco JV, Wright RS, Williams BA, Kopecky SL, Dvorak DL, Reeder GS, Miller WL, for the Mayo Coronary Care Unit Group : Effect of diabetes on the mortality risk of cardiogenic shock in a community‐based population. Mayo Clin Proc 2003; 78(5): 561–566 [DOI] [PubMed] [Google Scholar]
  • 10. Edep ME, Brown DL: Effect of early revascularization on mortality from cardiogenic shock complicating acute myocardial infarction in California. Am J Cardiol 2000; 85: 1185–1188 [DOI] [PubMed] [Google Scholar]
  • 11. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines : ACC/AHA guidelines for the management of patients with ST‐elevation myocardial infarction: Executive summary. A report of the ACC/AHA task force on Practice Guidelines. Circulation 2004; 110: 9: e82–e292 [PubMed] [Google Scholar]
  • 12. Waksman, Weiss AT , Gotsman S, Hasin Y: Intra‐aortic balloon counterpulsation improves survival in cardiogenic shock complicating acute myocardial infarction. Eur Heart J 1993; 14: 71–74 [DOI] [PubMed] [Google Scholar]
  • 13. Moulopoulos SD, Stamateolopoulos SF, Nanas JN, Kontoyannis DA, Nanas SN: Effect of protracted dobutamine infusion on survival of patients in cardiogenic shock treated with intraaortic balloon pump. Chest 1993; 103: 248–252 [DOI] [PubMed] [Google Scholar]
  • 14. Goldberg RJ, Gore JM, Alpert JS, Osganian V, de Groot J, Bade J, Chen Z, Frid D, Dalen JE: Cardiogenic shock after acute myocardial infarction: Incidence and mortality from a community‐wide perspective, 1975 to 1988. N Engl J Med 1991; 325: 1117–1122 [DOI] [PubMed] [Google Scholar]
  • 15. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators : Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335: 217–225 [DOI] [PubMed] [Google Scholar]
  • 16. Feit F, Brooks MM, Sopko G, Keller NM, Rosen A, Krone R, Berger PB, Shemin R, Attubato MJ, Williams DO, Frye R, Detre KM: Long‐term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: Comparison with the randomized trial. BARI Investigators. Circulation 2000; 101: 2795–2802 [DOI] [PubMed] [Google Scholar]
  • 17. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359–1367 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES